Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04826523 | Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML) | completed | — | 150 | AbbVieINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice(VYSION) | completed | — | 113 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03011372 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | completed | Phase 2 | 47 | Incyte CorporationINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02684162 | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07203885 | AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment(LEAP) | completed | N/A | 10 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04188678 | Resiliency in Older Adults Undergoing Bone Marrow Transplant(REBOUND) | completed | — | 126 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT03118466 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 41 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT01316250 | Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia | completed | N/A | 13 | American University of Beirut Medical CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04609826 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)(DHODH) | completed | Phase 1 | 153 | Janssen Research & Development, LLCINDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05153343 | Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | completed | Phase 1 / Phase 2 | 31 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05470140 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | completed | Phase 1 | 9 | Allotera TherapeuticsINDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06389357 | Retun-to-school Adaptation Program for Children With Cancer(web-based) | completed | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06326697 | Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 32 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07188428 | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | completed | — | 2,298 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | completed | Phase 2 | 81 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 7 | Sep 22, 2025 | clinicaltrials |
| NCT04182100 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | completed | Phase 2 | 29 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04385160 | Myeloproliferative Neoplasms (MPN) and COVID-19(MPN-COVID) | completed | — | 552 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 9 | Sep 15, 2025 | clinicaltrials |
| NCT06734585 | Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant | completed | — | 114 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT04512105 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | completed | Phase 1 | 6 | University of California, IrvineOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT02619565 | Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes(MDS04) | completed | N/A | 349 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06986772 | TGRX-678 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07155382 | Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 | completed | — | 98 | Asan Medical CenterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07151820 | A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients | completed | — | 2,546 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | completed | Phase 1 / Phase 2 | 97 | Astellas Pharma IncINDUSTRY | 3 | Sep 2, 2025 | clinicaltrials |
| NCT07150793 | A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan | completed | — | 754 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06648512 | Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)(EXCYTE-2) | completed | — | 91 | Exscientia AI LimitedINDUSTRY | 3 | Aug 26, 2025 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT01660607 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | completed | Phase 1 / Phase 2 | 68 | Stanford UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04057040 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | completed | Phase 2 | 70 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT02793544 | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | completed | Phase 2 | 80 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03957915 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia(INA03) | completed | Early Phase 1 | 33 | Institut Paoli-CalmettesOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04994158 | MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis(MASCOT-R) | completed | — | 238 | Royal Free Hospital NHS Foundation TrustOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05419648 | Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)(MonSThr) | completed | — | 68 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05499611 | Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia(COALA) | completed | — | 120 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04621851 | Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation | completed | — | 260 | University of Milano BicoccaOTHER | 4 | Jul 29, 2025 | clinicaltrials |
| NCT01385423 | Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06659224 | The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma | completed | — | 2,631 | asmaa salama ibrahimOTHER | 1 | Jul 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 26, 2025source: clinicaltrials